Cystic Fibrosis Clinical Trials

Methods to Identify and Treat Severe Asthma Patients Project 2: Airway pH Phenotyping

Normal 0 false false false EN-US X-NONE X-NONE Airway pH in airway health and diseaseNot all people with asthma respond well to traditional treatments. This could be because of acid levels in a person’s airway. Acid in the airway inhibits the body’s response to infection and increases inflammation. If medical …

The CHEC-SC Cohort Study: CHaractErizing CFTR Modulated Changes in Sweat Chloride and their Association with Clinical Outcomes (the CHEC-SC study)

This study will collect contemporary sweat chloride values from cystic fibrosis patients prescribed and currently receiving commercially approved CFTR modulator therapies.

TEACH Trial: Testing the Effect of Adding CHronic Azithromycin to Inhaled Tobramycin. A randomized placebo-controlled double-blinded trial of azithromycin 500mg thrice weekly in combination with inhaled tobramycin

This is a study to examine the effect of combining chronic oral azithromycin with inhaled tobramycin in adolescent and adult subjects with cystic fibrosis who are chronically infected with P. aeruginosa.

A Phase 3 Open-label Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Tezacaftor in Combination With Ivacaftor in Subjects With Cystic Fibrosis Aged 6 Years and Older Homozygous or Heterozygous for the F508del-CFTR Mutation

The purpose of this study is to evaluate the long-term safety and tolerability of TEZ/IVA in subjects with cystic fibrosis aged 6 years and older, who are homozygous or heterozygous for F508del mutation.

Protocol for the collection and transfer of cystic fibrosis lungs for research purposes

The goal of this project is to secure lung, tissue and blood samples of no clinical or diagnostic value from patients with cystic fibrosis (CF), and provide them to qualified and approved medical researchers.

A Phase 3 2-part Open-label Study to Evaluate the Safety and Pharmacokinetics of Lumacaftor/Ivacaftor in Subjects 1 to Less Than 2 Years of Age With Cystic Fibrosis Homozygous for F508del

This study is being done to learn more about the safety and effects of the combination of Lumacaftor (LUM) and Ivacaftor (IVA) in patients with Cystic Fibrosis between 1 to less than 2 years of age.

None

None

None

None